Table 3.

Correlation between NSCLC patients with brain metastases and different driver genes

	Brain metastases (n = 153)			Non‐ brain metastasis (n = 399)
	At first visit 108 (n, %)	Follow‐up 45 (n, %)	Total 153 (n, %)	n, %
EGFR mutation	55 (50.9)	22 (48.9)	77 (50.3)	149 (37.3)*
18 exons	2 (1.9)	0 (0)	2 (2.5)	4 (1.0)
19 exons	20 (18.5)	10 (22.2)	30 (39.0)	56 (14.0)
20 exons	4 (3.7)	1 (2.2)	5 (6.5)	5 (1.3)
21 exons	18 (16.7)	10 (22.2)	28 (3.6)	51 (12.8)
Double point mutations	11 (10.2)	1 (2.2)	12 (1.5.6)	33 (8.3)
ALK fusion mutation	4 (3.7)	5 (11.1)	9 (5.9)	13 (3.3)*
KRAS mutation	6 (5.6)	6 (13.3)	12 (7.8)	43 (10.8)*
ROS‐1 fusion mutation	0 (0)	0 (0)	0 (0.0)	3 (0.8)
BRAF mutation	0 (0)	2 (4.4)	2 (1.3)	1 (0.3)
ERBB2 mutation	0 (0)	1 (2.2)	1 (0.7)	6 (1.5)
RET fusion mutation	7 (6.5)	0 (0)	7 (4.6)	4 (1.0)
c‐MET mutation/amplification	0 (0)	1 (2.2)	1 (1.9)	2 (0.5)
Double gene mutation	2 (1.9)	2 (4.4)	4 (2.6)	8 (2.0)
No driven gene mutation	34 (31.5)	6 (13.3)	40 (26.1)	170 (42.6)

Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC, non‐small‐cell lung cancer.

Non‐brain metastasis vs brain metastases, *P < .05.